Université d'Angers, INSERM UMR 1063, Angers, France.
HP2, INSERM UMR 1042, Université Grenoble Alpes, Grenoble, France.
Thorax. 2019 May;74(5):496-499. doi: 10.1136/thoraxjnl-2018-212609. Epub 2018 Oct 26.
Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea-Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night). TRIAL REGISTRATION NUMBER: NCT01426607.
系统炎症和代谢紊乱是阻塞性睡眠呼吸暂停（OSA）与心血管疾病（CVD）相关的机制之一。在 109 名无明显心血管疾病的重度 OSA 患者中，在使用下颌前伸装置（MAD）（n=55）或假装置（n=54）治疗 2 个月前后，测量了炎症生物标志物（C 反应蛋白、白细胞介素-6、肿瘤坏死因子-α及其受体、脂联素、瘦素和 P 选择素）、葡萄糖和脂质代谢以及 N 末端脑钠肽前体。与假装置相比，MAD 降低了呼吸暂停低通气指数（p<0.001），但对循环生物标志物没有影响，尽管治疗依从性很高（每晚 6.6 小时）。试验注册号：NCT01426607。
